The Biogen Foundation's STAR Initiative--for Science, Teacher support, Access and Resources--is intended to strengthen and support educational offerings in these cities by helping increase access to STEM resources and opportunities for students currently underrepresented in STEM college or career pathways.
Through a coordinated network of grantees, STAR endeavors to help low-income students develop and sustain their interest in STEM, gain necessary STEM exposure and enrichment opportunities, and successfully transition into post-secondary education in pursuit of STEM careers.
The Biogen Foundation will soon be soliciting proposals from nonprofits providing services in the areas of STEM access, exploration, and preparedness for students in grades 6-12.
Successful applicants will partner with Cambridge and/or Somerville public schools by providing in- or out-of-school STEM awareness, exploration, and skill-building support and activities.
Organizations selected to receive grants will become part of a coordinated provider network managed by the Biogen Foundation. The STAR initiative is intended to complement, supplement, and strengthen the existing STEM education landscapes in Cambridge and Somerville.
The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located.
The foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives, and strengthening efforts to make science education and science careers accessible to diverse populations.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025